<em>Lancet, NEJM </em>Retract Surgisphere Studies on COVID-19 Patients
Lancet, NEJM Retract Surgisphere Studies on COVID-19 Patients
All authors other than company founder and CEO Sapan Desai were “unable to complete an independent audit of the data,” The Lancet states.
Lancet, NEJM Retract Surgisphere Studies on COVID-19 Patients
Lancet, NEJM Retract Surgisphere Studies on COVID-19 Patients

All authors other than company founder and CEO Sapan Desai were “unable to complete an independent audit of the data,” The Lancet states.

All authors other than company founder and CEO Sapan Desai were “unable to complete an independent audit of the data,” The Lancet states.

clinical research
Breaking
Concerns Build Over Surgisphere&rsquo;s COVID-19 Dataset
Concerns Build Over Surgisphere’s COVID-19 Dataset
Catherine Offord | Jun 2, 2020
NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.
Exclusive
Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere
Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere
Catherine Offord | May 30, 2020
Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.
WHO Halts Hydroxychloroquine Testing Over Safety Concerns
WHO Halts Hydroxychloroquine Testing Over Safety Concerns
Catherine Offord | May 27, 2020
A paper published in The Lancet reported that hospitalized COVID-19 patients taking the drug had a higher risk of death, although some researchers have raised questions about the data.
Support for Vaccine Challenge Trials Gains Momentum
Support for Vaccine Challenge Trials Gains Momentum
Shawna Williams | May 11, 2020
The idea of deliberately infecting volunteers with SARS-CoV-2 has garnered significant attention as a potential avenue to speedier development, as the World Health Organization weighs in with recommendations.
Remdesivir Shows Promise in Largest of Several Clinical Trials
Remdesivir Shows Promise in Largest of Several Clinical Trials
Catherine Offord | Apr 30, 2020
Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.
Journal Publisher Concerned over Hydroxychloroquine Study
Journal Publisher Concerned over Hydroxychloroquine Study
Kerry Grens | Apr 9, 2020
The report by Didier Raoult and colleagues that examined the use of the anti-malarial drug in a small number of COVID-19 patients receives criticism from the very society that published it.
Clinical Trial of COVID-19 Vaccine Begins in Seattle
Clinical Trial of COVID-19 Vaccine Begins in Seattle
Amy Schleunes | Mar 16, 2020
The first volunteer will receive a shot of the synthetic RNA vaccine today.
Global COVID-19 Cases Top 100,000
Global COVID-19 Cases Top 100,000
Lisa Winter | Mar 6, 2020
The WHO chief calls for swift action as universities in multiple countries shut down and researchers report kids can become infected.
How Aripiprazole&rsquo;s Promise for Treating Autism Fell Short
How Aripiprazole’s Promise for Treating Autism Fell Short
Hannah Furfaro | Feb 27, 2020
Aripiprazole, marketed as Abilify, is widely thought to be safer than risperidone, the only other drug approved for use in autistic children. A decade’s worth of data suggests that is not true.